• Molecular NameErgoloid mesylate
  • SynonymNA
  • Weight591.753
  • Drugbank_IDDB01049
  • ACS_NO8067-24-1
  • Show 2D model
  • LogP (experiment)2.615
  • LogP (predicted, AB/LogP v2.0)1.73
  • pkaN/A
  • LogD (pH=7, predicted)1.56
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.86
  • LogSw (predicted, AB/LogsW2.0)9.29
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors3
  • No.of HBond Acceptors10
  • No.of Rotatable Bonds5
  • TPSA118.21
  • StatusFDA approved
  • AdministrationOral, Parenteral
  • PharmacologyA mixture of the methanesulfonate salts of three dihydrogenated ergot alkaloids (dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine).
  • Absorption_value25.0
  • Absorption (description)Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding98.5
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life3.5 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A